Red Pill or Blue Pill?Red Pill first - let’s stick to some harsh realities, but using technical analysis only.
Why the harsh crash?
We were rejected at the Value Area high at $972, followed by another rejection at the 0.786 Fibonacci level at $916, along with the top of the flag pattern of this giant bull flag. This wa
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
491.39 THB
364.17 B THB
1.55 T THB
849.83 M
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
TH0150123907
FIGI
BBG01SRM8FN2
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
LLY - looking to reach the previous high ?=======
Volume
=======
-slight decreasing volume
==========
Price Action
==========
- Latest downtrend broken
- Change of trend observed
=========
Oscillators
=========
- Ichimoku, price above cloud, green kumo expanding, base + conv + lagging above sign of piercing clouds
- MACD still bullish
Eli Lilly ($LLY) – Brief AnalysisNYSE:LLY The stock remains in a downward channel (resistance ~772–780 $, support ~720–709 $, key risk level — 680 $).
Current price (~752 $) is around the middle of the channel (Fib 0.5). There’s pressure from the upper boundary.
Entry points:
750–755 $ (aggressive, with retracement risk)
Above
LLY - Beware the MotherbarTaking a closer look at the Eli Lilly chart and noticed that there is a box setup forming on the daily time frame. Specifically this box is the product of a mother bar.
If you take a look the last 4 daily candles have more or less traded within the body of the XXL green candle on the left.
I wou
Healthcare Heat check — $LLY (weekly) momentum brewing NYSE:LLY is showing a clean contracting wedged on the weekly chart and currently printing a big green week. Looks like a breakout attempt into real momentum. Long-term trend intact with price set comfortably above 200 SMA.
Healthcare looks like it’s getting rotation & leadership again with names
ELI LILLY COMPANY - STOCK REPORTExecutive Summary
Eli Lilly and Company (LLY) has delivered strong revenue and profit growth driven by blockbuster GLP‑1 therapies (Mounjaro, Zepbound) and continued pipeline progress in oncology and cardiometabolic indications. As of 26 Sep 2025 the company shows robust margins, strong free cash
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043Yield to maturity
5.70%
Maturity date
Sep 14, 2043
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044Yield to maturity
5.65%
Maturity date
Jun 15, 2044
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047Yield to maturity
5.36%
Maturity date
May 15, 2047
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065Yield to maturity
5.35%
Maturity date
Oct 15, 2065
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065Yield to maturity
5.34%
Maturity date
Feb 12, 2065
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064Yield to maturity
5.32%
Maturity date
Feb 9, 2064
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059Yield to maturity
5.32%
Maturity date
Mar 15, 2059
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064Yield to maturity
5.30%
Maturity date
Aug 14, 2064
US532457BY3
Eli Lilly and Company 2.25% 15-MAY-2050Yield to maturity
5.29%
Maturity date
May 15, 2050
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063Yield to maturity
5.28%
Maturity date
Feb 27, 2063
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054Yield to maturity
5.25%
Maturity date
Feb 9, 2054
See all LLY80 bonds